Medpace Renews Partnership with SCRS
Ellicott City, MD – The Society for Clinical Research Sites (SCRS) today announced Medpace has extended its commitment as a Global Impact Partner (GIP) by two years. Medpace will continue to serve on the SCRS Global Impact Board at an executive level, and work with the SCRS Leadership Council on strategic initiatives to promote high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
“When Global Impact Partners renew their partnership with us, they demonstrate their commitment to site sustainability,” said Christine Pierre, president of SCRS. “We are proud of our partnership with Medpace and look forward to our continued collaboration.”
“Medpace is pleased to continue our relationship with SCRS on the Global Impact Board,” said Susan E. Burwig, Medpace Executive Vice President, Operations. “Successful clinical trials rely on a CRO’s access to the best quality investigative sites. Working with other Global Impact Partners allows us to collaborate with industry leaders, producing better solutions for site management and enabling us to continue our reputation of delivering the highest quality studies for our sponsors.”
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries. To learn more, visit www.medpace.com.
About SCRS
SCRS is a global trade organization founded in 2012 which represents more than 4,000 research sites in 45 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Our Voice. Our Community. Your Success. Join the community and collaborate with the global experts in site sustainability. Visit MySCRS.org.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
